+34 914 524 941    info@algenex.com

About ALGENEX

Inspiring the future of biologics production

Founded in 2005 by Dr. Jose M. Escribano and Dr. Covadonga Alonso, ALGENEX specializes in the baculovirus vector-based innovative technologies to manufacture recombinant proteins used to produce vaccines, diagnostic reagents and therapeutic molecules. The company operates in Madrid, Spain.
Founded in 2005 by Dr. Jose M. Escribano and Dr. Covadonga Alonso, ALGENEX specializes in the baculovirus vector-based innovative technologies to manufacture recombinant proteins used to produce vaccines, diagnostic reagents and therapeutic molecules. The company operates in Madrid, Spain.
qodef-team-image
Operations Manager

Romy M. Dalton

Operations Manager

qodef-team-image
V&A Executive

Lieven De Smedt

V&A Executive

qodef-team-image
Chief Financial Manager

Santiago López

Chief Finantial Officer

qodef-team-image
Chief Executive Officer

Jaime Aparicio

Senior Consultant

JAS_Romy_PE_16_044_redonda copia

Romy Dalton

Operations Manager

Jaime_redonda

Jaime Aparicio

Interim Chief Executive Officer

Lieven-De-Smedt

Lieven De Smedt

V&A Executive

Santiago-Lopez

Santiago López

Chief Finantial Officer

ALGENEX’s Management Team includes experienced and respected biotechnology professionals providing strong scientific analysis supporting business management’s efforts in innovative technology collaborations and creative business development. ALGENEX’s Team is creating a world-class biotechnology company with a strong track record of success.
ALGENEX is backed by private venture capital firms like Unirisco and Biotori and sponsored by the Central and Regional Governments (Comunidad de Madrid, CDTI, ENISA and the Spanish Science and Technology Ministry).
ALGENEX’s Management Team includes experienced and respected biotechnology professionals providing strong scientific analysis supporting business management’s efforts in innovative technology collaborations and creative business development. ALGENEX’s Team is creating a world-class biotechnology company with a strong track record of success.
ALGENEX is backed by private venture capital firms like Unirisco and Biotori and sponsored by the Central and Regional Governments (Comunidad de Madrid, CDTI, ENISA and the Spanish Science and Technology Ministry).
TopBac Circulo
ALGENEX is proprietary of several technology platforms which include, among others, improved baculovirus vectors (TopBac®-modified baculoviruses), the use of Trichoplusia ni chrysalises as living bioreactors (CrisBioTM technology) and immunopotentiators such as APCH 1 or Sphere molecules.
Crisbio Circulo
TopBac Circulo
ALGENEX is proprietary of several technology platforms which include, among others, improved baculovirus vectors (TopBac®-modified baculoviruses), the use of Trichoplusia ni chrysalises as living bioreactors (CrisBioTM technology) and immunopotentiators such as APCH 1 or Sphere molecules.
Crisbio Circulo
TopBac Circulo
ALGENEX is proprietary of several technology platforms which include, among others, improved baculovirus vectors (TopBac®-modified baculoviruses), the use of Trichoplusia ni chrysalises as living bioreactors (CrisBioTM technology) and immunopotentiators such as APCH 1 or Sphere molecules.
Crisbio Circulo

A step forward in the baculovirus-based recombinant technologies

Record productivities

Development speed

Cost reductions

Success producing proteins difficult-to-express

10

years of experience in biotechnology

ALGENEX has licensed some of these technologies to top international companies for the production of diagnostic reagents and vaccines and co-develops several veterinary vaccines with top companies from Europe and USA.
160

molecules succesfully produced

ALGENEX has licensed some of these technologies to top international companies for the production of diagnostic reagents and vaccines and co-develops several veterinary vaccines with top companies from Europe and USA.
10

years of experience in biotechnology

160

molecules succesfully produced

10

years of experience in biotechnology

ALGENEX has licensed some of these technologies to top international companies for the production of diagnostic reagents and vaccines and co-develops several veterinary vaccines with top companies from Europe and USA.
160

molecules succesfully produced